

Chicago Biomedical Consortium

presents

CBC Accelerator Network:

Presentations of the CBC Accelerator Award Spring 2018 Letters of Intent (LOIs)

Thursday: February 1, 2018 Thursday: February 8, 2018

4:00 - 7:00 PM

Prentice Women's Hospital Pavilion Conference Center 3rd Floor, Room L South 250 East Superior Street Chicago, Illinois 60611





CBC MISSION

The mission of the Chicago Biomedical Consortium (CBC) is to stimulate collaboration among scientists at Northwestern University, The University of Chicago, the University of Illinois at Chicago and others to accelerate discovery that will transform biomedical research and improve the health of humankind. The CBC will:

- Stimulate research and education that bridge institutional boundaries,
- Enable collaborative and interdisciplinary research that is beyond the range of a single institution,
- Mentor and develop a strong cadre of biomedical leaders, researchers, and entrepreneurs in Chicago,
- Enhance and promote the development of the biomedical ecosystem in Chicago,
- Facilitate development of therapeutics that will, over the long term, improve the health of citizens of Chicago and beyond.

CBC LEADERSHIP

Lucy Godley, MD, PhD, Scientific Director, The University of Chicago T: 773-702-4140, E: Igodley@medicine.bsd.uchicago.edu

Brian K. Kay, PhD, Scientific Director, University of Illinois at Chicago T: 312-355-0668, E: bkay@uic.edu

Richard Morimoto, PhD, Scientific Director, Northwestern University T: 847-491-3340, E: r-morimoto@northwestern.edu

Jim Audia, PhD, Executive Director, Northwestern University T: 847-467-6745, E: jeaudia1@northwestern.edu

CBC STAFF

Karen Snapp, DDS, PhD, Senior Associate Director, Northwestern University T: 847-467-0633, E: ksnapp@northwestern.edu

Nancy Tyrrell, Associate Director for Translational Activities, Northwestern University T: 847-467-1094, E: nancy.tyrrell@northwestern.edu

Kimberly Corn, Associate Director, Business Operations and Finance, Northwestern University T: 847-467-0357, E: k-corn@northwestern.edu

Jola Glotzer, MD, Communications Director, The University of Chicago T: 773-834-5132, E: jolaglotzer@uchicago.edu

Corinna Kitcharoen, MBA, Program Coordinator, University of Illinois at Chicago T: 312-996-1311, E: ckitch1@uic.edu



Part I	PROGRAM	3rd Floor, Room L South		
4:00 PM	PARTICIPANTS' SELF-INTRODUCTION Each person introduces themselves and their institution/affiliation.			
4:10 PM	Spring 2018 application cycle.	ator Award program; status of the or and Nancy Tyrrell , CBC Associate		
4:15 PM	PRESENTATIONS OF LETTERS OF INTENT (LOIs) FOR THE CBC ACCELERATOR AWARD PROGRAM Moderators: Jim Audia and Nancy Tyrrell At each February CBCAN meeting, up to 5 Letters of Intent (LOIs) we be presented. Please see the program booklet insert for the list and schedule of the selected LOIs to be presented at today's CBCA meeting. The insert includes a brief summary of each LOI and form for CBCAN participants to provide comments and suggestion which will be made available to LOI presenters. Please note that although we ask CBCAN participants to provide their names on the forms, this is for CBC administrative purposes only—the comments to the LOI presenters will be provided anonymously.			
5:55 PM	LOI presentations cannot excee of Q&A. Anticipated start times allowing 4:15 PM; 4:35 PM; 4:55 PM; CONCLUDING REMARKS	d 8 minutes, followed by 10 minutes for 5 LOI presentations:		
Part II	Jim Audia and Nancy Tyrrell NETWORKING	3rd Floor, Harris Family Atrium		

NETWORKING RECEPTION


ADJOURN

6:00 PM 7:00 PM



CBC ACCELERATOR NETWORK (CBCAN)

The CBC Accelerator Network (CBCAN) has been established as a New Forum to regularly bring together academic and industry scientists as well as other members of the biotech community to present and discuss ideas for commercialization. CBCAN aims to convene entrepreneurially-minded faculty, postdoctoral fellows and graduate students, along with industry experts and technology transfer officers, building a community, encouraging interactions, and educating academic researchers about market realities and the paths to realize their translational and commercial objectives. The CBCAN program will be central to and fully integrated with other CBC Phase 2 new initiatives.



CBC ACCELERATOR AWARD PROGRAM

In January 2018, the CBC launched a new **Accelerator Award program** to support translational research and provide university researchers with "early commercial guidance." Accelerator Awards will be used to support the initial, and therefore highest risk, stage of commercially-directed research focused on the **development of a therapeutic or an associated biomarker or diagnostic.** The program will encourage interactions between academic researchers and industry/pharmaceutical experts early in the development of projects and provide advice to award recipients in setting and progressing toward commercialization milestones. Award recipients will be mentored by faculty, industry experts, tech transfer officers and CBC personnel. Accelerator awardees will provide project updates at CBCAN meetings.

Letters of Intent (LOIs) to submit translational research projects are required for initial evaluation by a team of reviewers **(Accelerator Review Board, ARB)** that includes university faculty with scientific, translational and entrepreneurial expertise, tech transfer officers and industry scientists (see p. 6). Selected LOIs will be presented at a CBCAN meeting and finalists will be invited to submit **full proposals**, which must discuss commercial potential, milestones and deliverables, and incorporate the ARB feedback from the CBCAN. Accelerator Awards will be for \$100,000 for one year.

Awarded projects that have **met proposed milestones** during the first year may be invited to apply for \$150,000 for one additional year.



ACCELERATOR AWARD DETAILS AND ELIGIBILITY:

- Applicants must be tenured or tenure-track faculty with research programs at Northwestern University, The University of Chicago, and/or University of Illinois at Chicago. Faculty with full time appointments on the clinical track at each of the institutions are also eligible to apply. Applicants must have their own designated laboratory space. Individuals who carry faculty appointments with parenthetical rank, are not eligible for tenure, and do not have their own laboratory space are not eligible to apply.
- Although collaborative proposals are encouraged, there is no specific requirement for cross-institutional collaboration.
- Applicants may have created a company to pursue translation of their innovation, but there is no expectation or requirement for so doing. The CBC encourages applications prior to or without company formation.
- Multiple applications can be submitted from each institution.
- There is no expectation that Accelerator Awards will be distributed evenly among the CBC institutions.
- Proposals should show both innovation and scientific merit.
- The project should be focused on the development of a therapeutic or associated diagnostic or biomarker, built around a compelling hypothesis and focused on gathering data that advances the hypothesis and discharges key translational risks.
- Research teams should not already be funded for the same (or closely related) specific aims and/or milestones.
- Research projects described in Accelerator applications cannot be under review at other funding institutions/agencies to support the same (or closely related) specific aims and/or milestones.
- A PI may participate in only one application per round.
- Ongoing and active participation in the CBCAN program is a requirement for Accelerator Award recipients.

Key dates for the 2018 Accelerator Award program application rounds:

Application Round	LOI Online Submission	Invitation to Submit a Full Proposal	Full Proposal Online Submission	Funding Decisions Expected	Anticipated Start Date
Spring 2018	Jan. 8-12, 2018	March 1, 2018	April 9-13, 2018	May 14, 2018	July 1, 2018
Fall 2018*	June 4-8, 2018	August 29, 2018	Sept. 24-28, 2018	Oct. 26, 2018	Dec. 1, 2018

^{*}Tentative and subject to change. Please, check the CBC website for the most current updates.



Accelerator Review Board (ARB)

Accelerator LOIs and proposals are evaluated by the ARB, composed of faculty and professionals associated with technology transfer offices and core facilities from UIC, NU, and UChicago, along with representatives from the pharmaceutical, biotechnology and investment communities. The ARB will approve projects based on significance, translational potential, marketability of the proposed product, preliminary data, and the soundness of the proposed milestones to discharge key elements of risk.

CURRENT ARB MEMBERSHIP:

Neelum Aggarwal, MD

Associate Professor, Department of Neurological Sciences, Rush Medical College Clinical Core Co-Leader, Rush Alzheimer's Disease Center

Arun Bhatia, MBA

Program Director, MATTER

Laura Bloem, PhD

Research Associate Professor, Department of Medicinal Chemistry and Pharmacognosy UICentre, University of Illinois at Chicago

Lisa Dhar, PhD

Director of New Business Ventures for Engineering, Innovation and New Ventures (INVO), Northwestern University

Terri Fraterrigo, MS

Director of Operations and Outreach, Center for Molecular Innovation and Drug Discovery (CMIDD), Northwestern University

Nancy Harvey, PhD, MBA

Managing Director; Director, Technology Commercialization and Licensing Director, Venture Growth, Polsky Center for Entrepreneurship and Innovation University of Chicago

Jason Hickok, PhD

Research Assistant Professor, Department of Medicinal Chemistry and Pharmacognosy Assistant Director, UICentre University of Illinois at Chicago

Kathryn Hyer

Chief Business Officer, Diagnostic Photonics Co-Lead, PROPEL

Vara Prasad Joshyula, PhD

Senior Director, GCIC Product Development (Therapeutics); Innovations, Cleveland Clinic

***Brian Layden, MD, PhD

Chief, Division of Endocrinology, Diabetes, and Metabolism, University of Illinois at Chicago

Kevin Lynch, PhD, MBA

Vice President, Search & Evaluation, Partnerships, AbbVie

Laurens Mets, PhD

Associate Professor, Department of Molecular Genetics and Cell Biology, Committee on Genetics University of Chicago

Raymond Moellering, PhD

Assistant Professor, Department of Chemistry University of Chicago

Michael Myers, PhD

Sr. Director, LRL – Due Diligence Eli Lilly and Company

Suseelan Pookote, PhD

Interim Director, Leadership, Management & Medicine, Office of Technology Management, University of Illinois at Chicago

Gary Schiltz, PhD

Research Professor, Department of Pharmacology; Deputy Director, Center for Molecular Innovation & Drug Discovery (CMIDD); Director of Chemistry, ChemCore Northwestern University

James P. Sullivan, PhD

Vice President, Discovery, AbbVie

***Gregory Thatcher, PhD

Professor, Department of Medicinal Chemistry and Pharmacognosy Director, UlCentre University of Illinois at Chicago

Kapila Viges

Director, Strategy Insights & Planning, Oncology Group, ZS Associates

Ze-Qi Xu, PhD

Vice President, Operations RiMO Therapeutics, Inc.

^{***}Recused from ARB in Spring 2018 round

Notes



_

